GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » EV-to-EBITDA

Affimed NV (Affimed NV) EV-to-EBITDA : -0.20 (As of May. 11, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Affimed NV EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Affimed NV's enterprise value is $22.22 Mil. Affimed NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-110.28 Mil. Therefore, Affimed NV's EV-to-EBITDA for today is -0.20.

The historical rank and industry rank for Affimed NV's EV-to-EBITDA or its related term are showing as below:

AFMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33492.1   Med: -2.41   Max: 20.66
Current: -0.2

During the past 12 years, the highest EV-to-EBITDA of Affimed NV was 20.66. The lowest was -33492.10. And the median was -2.41.

AFMD's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 9.49 vs AFMD: -0.20

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Affimed NV's stock price is $5.25. Affimed NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.639. Therefore, Affimed NV's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Affimed NV EV-to-EBITDA Historical Data

The historical data trend for Affimed NV's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV EV-to-EBITDA Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.81 -8.09 -7.64 -0.03 -0.32

Affimed NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 0.37 0.21 0.08 -0.32

Competitive Comparison of Affimed NV's EV-to-EBITDA

For the Biotechnology subindustry, Affimed NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affimed NV's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Affimed NV's EV-to-EBITDA falls into.



Affimed NV EV-to-EBITDA Calculation

Affimed NV's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=22.221/-110.284
=-0.20

Affimed NV's current Enterprise Value is $22.22 Mil.
Affimed NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-110.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affimed NV  (NAS:AFMD) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Affimed NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.25/-7.639
=At Loss

Affimed NV's share price for today is $5.25.
Affimed NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.639.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Affimed NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Affimed NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Affimed NV (Affimed NV) Business Description

Traded in Other Exchanges
Address
Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Affimed NV (Affimed NV) Headlines

From GuruFocus